Aptose Biosciences Inc. (NASDAQ: APTO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
Aptose Biosciences, Inc. - Common Shares (APTO)
Last aptose biosciences, inc. - common shares earnings: 3/10 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aptose.com/investors
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
APTO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APTO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APTO alerts
High impacting Aptose Biosciences, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
APTO
News
- Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Aptose Biosciences Inc. (NASDAQ: APTO) had its price target lowered by analysts at HC Wainwright from $7.00 to $2.00. They now have a "buy" rating on the stock.MarketBeat
- Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy [Yahoo! Finance]Yahoo! Finance
- Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet TherapyGlobeNewswire
- Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
APTO
Earnings
- 8/8/24 - Beat
APTO
Sec Filings
- 11/20/24 - Form 8-K
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- APTO's page on the SEC website